Welcome to Coulter Partners Global (English)

14 July 2022

Top hires for VC & PE portfolio companies Q2-2022

Search Highlights

Recent top global hires for Venture Capital and Private Equity backed companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech.

This quarter’s successful placements include:

Function Focus area Location
CEO Advanced machine learning tools US
CEO Drug discovery services UK
CEO Synthetic biology technologies UK
CEO Switzerland In/outpatient services Nordics
Chief Scientific Officer Antibody-drug conjugates (ADCs) Denmark
Chief Medical Officer Digital therapeutics Sweden
Chief Medical Officer CNS diseases Singapore
Chief Business Officer Immuno-oncology and vaccines Finland
Chief Commercial Officer Contract research organisation US
Commercial Head Europe A.I.-based neuro-diagnostics Nordics
Head Medicinal Chemistry Discovery tools UK
VP Operations Precision medicine technologies US
VP Molecular Pharmacology RNA interference US
VP Clinical Development RNA therapeutics US
VP Finance Immuno-oncology Switzerland
Investment Partner Private equity investor France

Newly opened projects include:

Function Focus area Location
CEO Oncology devices Italy
CEO Diagnostics technology UK
CEO Immuno-oncology Belgium
Chief Business Officer Gene therapies Netherlands
Chief Medical Officer Radiopharmaceuticals China
Chief Medical Officer Digital therapeutics France
Chief Financial Officer Genomic technologies US
Chief Commercial Officer US Molecular cartography Germany
Chief Technology Officer Contract development organisation US
SVP Research Gene delivery technologies US
VP Intellectual Property Protein degradation technology UK
General Manager UK Digital devices and therapeutics US
Board Director Advanced reagents Sweden
Chair Active pharmaceutical ingredients Switzerland


A new version of Coulter Partners is available.